MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

被引：0
|
作者：
Neil Portman
Heloisa H. Milioli
Sarah Alexandrou
Rhiannon Coulson
Aliza Yong
Kristine J. Fernandez
Kee Ming Chia
Ensar Halilovic
Davendra Segara
Andrew Parker
Sue Haupt
Ygal Haupt
Wayne D. Tilley
Alex Swarbrick
C. Elizabeth Caldon
Elgene Lim
机构：
[1] Garvan Institute of Medical Research,St. Vincent’s Clinical School, Faculty of Medicine
[2] University of New South Wales Sydney,Tumor Suppression Laboratory
[3] Peter MacCallum Cancer Centre,Sir Peter MacCallum Department of Oncology
[4] The University of Melbourne,Adelaide Medical School
[5] Novartis Institutes of Biomedical Research,undefined
[6] The University of Adelaide,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
Breast cancer; MDM2; Oestrogen receptor; CDK4/6 inhibitor; p53;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy
    Lenihan, C.
    Bouchekioua-Bouzaghou, K.
    Abdulghani, R.
    Chupin, J.
    Shia, A.
    Schmid, P.
    CANCER RESEARCH, 2017, 77
  • [42] CDK4/6 inhibition in early and metastatic breast cancer: A review
    de Groot, A. F.
    Kuijpers, C. J.
    Kroep, J. R.
    CANCER TREATMENT REVIEWS, 2017, 60 : 130 - 138
  • [43] Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers
    Freelander, Allegra
    Laven-Law, Geraldine
    Eshraghi, Leila
    Chia, Kee Ming
    Pickering, Marie
    Yong, Aliza
    Wilkinson, Ashleigh
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Hickey, Theresa E.
    Tilley, Wayne D.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [44] Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer
    Jansen, V. M.
    Bhola, N. E.
    Bauer, J. A.
    Formisano, L.
    Moore, P.
    Koch, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2016, 76
  • [45] Investigating CDK4/6 inhibition in triple negative breast cancer
    Guo, Qiuchen
    Goreczny, Gregory J.
    Spasic, Milos
    Maynard, Adam
    McAllister, Sandra S.
    CANCER RESEARCH, 2021, 81 (04)
  • [46] Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
    Jansen, Valerie M.
    Bhola, Neil E.
    Bauer, Joshua A.
    Formisano, Luigi
    Lee, Kyung-Min
    Hutchinson, Katherine E.
    Witkiewicz, Agnieszka K.
    Moore, Preston D.
    Estrada, Monica Valeria
    Sanchez, Violeta
    Ericsson, Paula G.
    Sanders, Melinda E.
    Pohlmann, Paula R.
    Pishvaian, Michael J.
    Riddle, David A.
    Dugger, Teresa C.
    Wei, Wenyi
    Knudsen, Erik S.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2017, 77 (09) : 2488 - 2499
  • [47] RNA interference kinome-wide screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition ER-positive breast cancer
    Jansen, Valerie M.
    Bhola, Neil E.
    Bauer, Joshua A.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2015, 75
  • [48] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Kappel, Coralea
    Elliott, Mitchell J.
    Kumar, Vikaash
    Nadler, Michelle B.
    Desnoyers, Alexandra
    Amir, Eitan
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [49] CDK4/6 inhibition as maintenance therapy in ovarian cancer.
    Iyengar, Mangala
    Coffman, Lan
    Buckanovich, Ronald
    CLINICAL CANCER RESEARCH, 2016, 22
  • [50] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Coralea Kappel
    Mitchell J. Elliott
    Vikaash Kumar
    Michelle B. Nadler
    Alexandra Desnoyers
    Eitan Amir
    Scientific Reports, 14
12345